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What Causes Tolerance to
Nitroglycerin?: The 100 Year Old
Mystery Continues*
MILTON PACKER, MD, FACC
Nell' York, Nell' York
No pleasure lasts long unless there is variety in it.
(PlIblilills Syrills)
Organic nitrates are among the oldest and most widely used
drugs in cardiovascular medicine. Although short-term ther-
apy with sublingual and intravenous nitroglycerin is effective
in the treatment of a variety of cardiac emergencies, at-
tempts to extend the benefits of this drug to the long-term
management of patients have been disappointing. Tolerance
develops rapidly to the hemodynamic and clinical effects of
nitrates when they are administered continuously or at
frequent intervals; consequently, controlled trials often have
been unable to show that prolonged use of these drugs
produces symptomatic improvement. Such observations are
not new: tolerance to nitroglycerin was first reported in the
clinical setting in 1888 (I). However, despite intensive study
during the last 100 years, the cause of nitrate tolerance
remains a mystery.
Three mechanisms have been proposed to explain the
development of tolerance to nitroRlycerin: I) depletion of
sulfhydryl cofactors that are required for the vasodilator
action of the drug, 2) activation of endogenous vasoconstric-
tor mechanisms that limit the drug's circulatory effects, and
3) expansion of intravascular volume that results in loss of
hemodynamic efficacy. Whereas previous research in the
field has largely focused on one mechanism at a time, the
report by Dupuis et al. (2) in this issue of the Journal is the
first attempt to explore all three mechanisms simultaneously
in a single study. One conclusion emerges clearly from this
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work: the development of tolerance is far more complicated
than anyone had expected.
Intracellular sulfhydryl depletion as a cause of tolerance.
Nitroglycerin exerts its vasodilating effects by stimulating
guanylate cyclase inside the vascular smooth muscle cell',
the resulting increase in cyclic guanosine monophosphate
(GMP) causes relaxation of blood vessels by reducing cyto-
solic calcium (3-5). Nitroglycerin cannot activate guanylate
cyclase directly, however. To do so, the drug must be
metabolically activated to form nitric oxide or S-nitrosothi-
ols, but such conversion requires the presence of cysteine
(6), Tolerance to the drug's vasodilating effects is accompa-
nied by a decreased rate of activation of guanylate cyclase
(4,6.7), which seems to be related to a reduction in the
metabolic conversion of nitroglycerin rather than a change in
the function of the enzyme (8). On the basis of this model,
several investigators have suggested that a depletion of
intracellular sulfhydryl cofactors (cysteine) might explain
the reduced metabolic conversion of nitroglycerin and
thereby the development of tolerance to the drug (3,9).
The sulfhydryl depletion hypothesis has become the focus
of considerable controversy. The incubation of tolerant
arterial strips with a variety of sulfhydryl cofactors in vitro
has produced partial reversal of tolerance in some laborato-
ries (9-11) but not others (12-14). Similarly, the administra-
tion of N-acetylcysteine and methionine (which are con-
verted into cysteine in vivo) into animals and patients made
tolerant to organic nitrates has reversed tolerance in some
studies (15-19) but not in others (20,21). How can the
proponents of the sulfhydryl depletion hypothesis explain
the failure of sulfhydryl cofactors to reverse tolerance in
isolated arterial rings? Veins, rather than arteries, may be
the primary site of tolerance reversal by sulfhydryl cofactors
because nitroglycerin stimulates the synthesis of cyclic GMP
more markedly in veins than in arteries (5,11,22). How do
skeptics of the sulfhydryl depletion hypothesis explain the
hemodynamic responses seen when sulfhydryl cofactors are
given to nitrate-tolerant subjects? Sulfhydryl cofactors may
enhance the effects of nitroglycerin (by promoting the for-
mation of S-nitrosothiols) whether or not a tolerant state
exists (23,24); according to this view. the effects of N-ace-
tylcysteine in vivo are the result of a nonspecific potentiation
rather than a specific reversal of tolerance (20,25). Fung and
coworkers (26) have postulated that nitroglycerin and N-ace-
tylcysteine can interact extracellularly to form S-nitrosothi-
ols, which. after entering the cell, can stimulate the produc-
tion of cyclic GMP directly. Presumably this may occur
whether or not the metabolic conversion of nitroglycerin is
impaired or tolerance exists.
Do the data of Dupuis et al. (2) in the present study
support or refute the suiflzydryl depletion hypothesis? In this
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study the addition of N-acetylcysteine completely prevented
the development of tolerance to the initial effect of nitroglyc-
erin on mean right atrial pressure, partially prevented toler-
ance to the action of the drug on pulmonary artery and
wedge pressures but did not alter the development of toler-
ance to the drug's effect on mean arterial pressure and
systemic vascular resistance. The favorable effects ofN-ace-
tylcysteine on right and left ventricular filling pressures
might have been even more apparent if the authors had
carried out a paired analysis in patients who received two
infusions of nitroglycerin (with and without N-acetylcys-
teine) instead of analyzing the responses to two infusions in
the same patient as if they had been given to different people.
In any case, their data support the concept that sulfhydryl
cofactors are more likely to interfere with the development
of nitrate tolerance in veins than arteries; other mechanisms,
such as neurohormonal activation, may be responsible for
the development of tolerance in arterial resistance vessels
(27).
Yet the study by Dupuis et al. (2) also provides a stronf?
argument against the sulfhydryl depletion hypothesis. In
their study the coadministration of nitroglycerin and N-ace-
tylcysteine was frequently accompanied by episodes of
hypotension, which were not seen in patients who received
nitroglycerin alone; similar episodes have been reported by
Horowitz et al. (28). These findings indicate that sulfhydryl
cofactors can potentiate the hemodynamic effects of nitro-
glycerin in the nontolerant state; therefore, these data sup-
port the existence of a nonspecific interaction. Why did the
early hypotension seen by Dupuis et al. (2) disappear after
24 h? Kowaluk et al. (8) have shown that blood vessels may
become tolerant to S-nitrosothiols when exposed to them for
long periods. The secondary development of nitrosothiol
tolerance may explain the apparent lack of sulfhydryl effects
in the study of Dupuis et al. (in which N-acetylcysteine and
nitroglycerin were infused together for 24 h), whereas favor-
able sulfhydryl effects have been reported in studies (15,16)
in which the two agents were combined for only brief
intervals.
Neurohormonal activation as a cause of tolerance. Like
other organic vasodilators, organic nitrates may activate
endogenous neurohormonal systems (specifically, the sym-
pathoadrenal axis and the renin-angiotensin system); the
resulting vasoconstriction and sodium retention may, in
turn, limit the pharmacologic effects of these drugs (27 ,29).
These reflex mechanisms become evident as rebound phe-
nomena when, on abrupt discontinuation of a short-acting
vasodilator, drug-mediated vasodilation rapidly disappears
leaving the reactive neurohormonal forces unopposed. The
occurrence of rebound hemodynamic events after the abrupt
withdrawal of nitroprusside and nitroglycerin suggests that
similar reactive mechanisms can limit the magnitude of
drug-mediated peripheral vasodilation and thereby contrib-
ute to the development of tolerance (30-32).
Strong evidence in favor of a role for neurohormonal
activation in the del'elopment of nitrate tolerance has come
from our own studies in human heart failure (14). Tolerance
produced by the continuous infusion of nitroglycerin for 48 h
was paralleled by an increase in heart rate, plasma renin
activity and body weight. These neurohormonal events
persisted for 2 to 3 h after the discontinuation of nitroglyc-
erin (at which time patients still showed evidence of toler-
ance) but were no longer apparent 24 h later (when respon-
siveness to nitroglycerin was restored). Intermittent (12
hourly) dosing with nitroglycerin, which successfully cir-
cumvented the development of tolerance, failed to activate
endogenous neurohormonal systems, whereas intermittent
dosing regimens that produced partial tolerance (4 hourly
and 8 hourly) were accompanied by moderate neurohor-
monal activation (33). Similar neurohormonal responses
have been observed in patients with ischemic heart disease
(34), although not necessarily in all reports (32,35). The close
concordance between neurohormonal activation and the loss
of nitroglycerin's hemodynamic efficacy suggests a role for
reactive vasoconstriction in the pathogenesis of nitrate tol-
erance in humans.
The data of Dupuis et al. (2) are consistent with the
hypothesis that neurohormonal actil'ation contributes to the
development of tolerance to nitrof?lycerin. In their study
tolerance was accompanied by an increase of plasma renin
activity after I and 6 h of continuous intravenous therapy.
The renin-angiotensin system may have been stimulated
either by the fall in blood pressure (which activates renal
baroreceptors) or by the decline in circulating levels of atrial
natriuretic peptide (because the peptide inhibits the secre-
tion of renin by the kidney [36]). Unfortunately, Dupuis et al.
performed no hormonal measurements at the time when
patients show the greatest development of tolerance-after
24 h of intravenous nitroglycerin therapy. This omission
limited their ability to confirm the existence of a close
relation between neurohormonal and hemodynamic events.
However, it is likely that neurohormonal systems remained
activated after 24 h in their study because heart rate was
increased significantly at that time. This pattern of response
is strikingly similar to that reported in our own studies (15).
The neurohormonal activation hypothesis raises the pos-
sibility that tolerance to nitroglycerin could be avoided if the
drug were given together with a neurohormonal antagonist.
Indeed, Levy et al. (37) reported that nitrate tolerance in
normal volunteers can be circumvented by the concurrent
administration of an angiotensin-converting enzyme inhibi-
tor. With respect to the sulfhydryl depletion hypothesis, it is
noteworthy that tolerance was prevented most successfully
in their study when a sulfhydryl-containing angiotensin-
converting enzyme inhibitor was employed.
Intravascular volume expansion as a cause of tolerance.
The finding that the prolonged administration of nitroglyc-
erin is accompanied by a decrease in the hematocrit (37,38)
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has led to the hypothesis that tolerance may be related to an
increase in intravascular volume, which would limit the
ability of the drug to decrease ventricular filling pressures.
Physicians have generally assumed that this hemodilution is
a consequence of the sodium retention that accompanies
activation of the renin-angiotensin system but this assump-
tion has never been critically assessed. The study of Dupuis
et al. (2) in this issue of the Journal represents the first
meticulous evaluation of nitroglycerin-induced hemodilution
in the clinical setting. These investigators noted that the
increase in intravascular volume seen during the infusion of
nitroglycerin was not accompanied by an increase in body
weight. This finding suggests that hemodilution is not the
result ofgeneralized sodium retention but is caused by a shift
of fluid from the extravascular into the intravascular space.
Such a shift might be related to preferential venodilation
(which would reduce the extravasation of fluid from the
capillaries to the extravascular space) or to the decrease in
circulating levels of atrial natriuretic peptide (because the
peptide can cause hemoconcentration [36]).
Can internal hemodilution explain the development of
tolerance to nitroglycerin? Hemodilution may explain why
tolerance develops more readily to the effects of nitroglyc-
erin on ventricular filling pressures than on cardiac output or
systemic vascular resistance (2,15,27,31). On the other hand,
most of the fluid shift noted by Dupuis et al. (2) was observed
during the 1st h of the infusion when the hemodynamic
effects of nitroglycerin were most marked; in contrast, little
additional hemodilution was observed between I and 6 h,
although the effects of nitroglycerin on mean arterial pres-
sure became significantly attenuated during this time. None-
theless, the careful measurements of Dupuis et al. provide
the basis for a provocative hypothesis that needs to be
thoroughly evaluated in future studies. If their hypothesis is
confirmed, diuretics may prove to be a useful intervention in
preventing tolerance to nitroglycerin in a fashion similar to
their utility in preventing tolerance to other vasodilator
drugs (39,40).
Conclusions. The available evidence suggests that multi-
ple mechanisms interact to promote the development of
tolerance to nitroglycerin. To make matters more compli-
cated, the relative importance of one pathway versus an-
other may not be constant but may depend on the status of
the patient, as well as the dose, duration and route of
administration of the nitrate being utilized. How can such a
complex interaction be investigated? Future work should
emphasize both basic and clinical investigations. Molecular
pharmacologic techniques can be applied to elucidate the
pathways utilized for the metabolic activation of nitroglyc-
erin. Such in vitro studies should not be relied on too
heavily, however, because experiments carried out in iso-
lated vascular rings may not be applicable to the clinical
setting where both neurohormonal activation and intravas-
cular fluid shifts may play important roles. The interactions
are probably so complex that the solution is not likely to
emerge for many years.
What should physicians do in the meantime to prevent the
development of tolerance? Should they routinely use N-ace-
tylcysteine, converting enzyme inhibitors or diuretics to
interfere with the three primary mechanisms that have been
implicated in this phenomenon? Although future studies may
eventually support the utility of these interventions, the only
worthwhile way to circumvent the development of tolerance
at the present time is to administer nitroglycerin intermit-
tently. Unfortunately, the intermittent use of nitrates cannot
produce a continuous therapeutic effect and is frequently
associated with intolerable side effects and rebound clinical
events (41,42). These important limitations of intermittent
therapy make it imperative that we solve the mystery of
nitrate tolerance as quickly as possible.
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